Primary tumor suppression was highly significant in the XRT + Anti-PD1 + RDB 1462, and XRT + RDB 1462 groups and the growth rate of secondary tumors was diminished, with substantial improvement in survival rates in the triple combination group.
← all excerpts
Novel engineered IL-2 Nemvaleukin alfa combined with PD1 checkpoint blockade enhances the systemic anti-tumor responses of radiation therapy.
1
—
—